Keyword Analysis & Research: foundationone
Keyword Research: People who searched foundationone also searched
Search Results related to foundationone on Search Engine
-
FoundationOne CDx | Foundation Medicine
https://www.foundationmedicine.com/test/foundationone-cdx
WEBA single test analyzes guideline-recommended genes in solid tumors, including companion diagnostic indications with a direct path to therapy. FoundationOne CDx also has national coverage for qualifying Medicare and Medicare Advantage patients across all solid tumors. All Solid Tumors.
DA: 11 PA: 25 MOZ Rank: 66
-
FoundationOne Liquid CDx | Foundation Medicine
https://www.foundationmedicine.com/test/foundationone-liquid-cdx
WEBFoundationOne®Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw. It is the only FDA-approved blood-based test to analyze over 300 genes**—making it the most comprehensive FDA-approved liquid biopsy on the market.
DA: 16 PA: 45 MOZ Rank: 63
-
Foundation Medicine | A World-leading Molecular Insights Company
https://www.foundationmedicine.com/
WEBFoundationOne Tracker. Add clarity to treatment response with personalized tissue-informed ctDNA monitoring, providing objective insights to help you understand your patients' response to treatment.
DA: 45 PA: 33 MOZ Rank: 56
-
FoundationOne®CDx
https://www.rochefoundationmedicine.com/home/services/cdx.html
WEBCDx. Our pioneering, FDA-validated, tissue-based, comprehensive genomic profiling service for solid tumours to help guide informed, personalised treatment decisions. 1−3. What is FoundationOne CDx? Genes and genomic signatures. Validation. IN-DEPTH REPORT. CLINICAL USE IN SOLID CANCERS.
DA: 2 PA: 31 MOZ Rank: 36
-
Foundation Medicine and Natera Announce the Launch of FoundationOne
https://www.natera.com/company/news/foundation-medicine-and-natera-announce-the-launch-of-foundationonetracker-personalized-circulating-tumor-dna-monitoring-assay-for-investigational-use-and-early-access-clinical-use/
WEBJan 9, 2023 · Cambridge, Mass. , & Austin, Texas, January 9, 2023 – Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Natera, Inc., a global leader in cell-free DNA testing, today launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.
DA: 70 PA: 91 MOZ Rank: 63
-
FoundationOne®CDx Receives FDA Approval as a Companion …
https://www.businesswire.com/news/home/20211208005268/en/FoundationOne%C2%AECDx-Receives-FDA-Approval-as-a-Companion-Diagnostic-for-BRAF-Inhibitor-Therapeutics-in-Melanoma
WEBDec 8, 2021 · FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs)...
DA: 5 PA: 5 MOZ Rank: 19
-
FDA Approves Blood Tests That Can Help Guide Cancer Treatment
https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-guardant-360-foundation-one-cancer-liquid-biopsy
WEBOct 15, 2020 · FoundationOne Liquid CDx, made by Foundation Medicine, was approved as a companion diagnostic for three lung cancer therapies and a prostate cancer therapy. Clinical studies to support additional companion diagnostic labels for both tests are ongoing.
DA: 53 PA: 2 MOZ Rank: 32
-
See more, do more - Roche Foundation Medicine
https://www.rochefoundationmedicine.com/content/dam/fmi-landing/en/documents/Patient_F1CDx_brochure_2020.pdf
WEBFoundationOne Liquid CDx will test for mutations in your blood which mainly contains circulating DNA from your primary tumour but also from metastases if the cancer has spread. FoundationOne Liquid CDx might provide an 'update' on how your cancer is responding to treatment without having to take a tissue sample and provide genomic …
DA: 46 PA: 16 MOZ Rank: 55
-
FoundationOne CDx Technical Information - Roche …
https://www.rochefoundationmedicine.com/f1cdxtech
WEBFoundationOne® CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burd...
DA: 35 PA: 5 MOZ Rank: 74
-
Foundation Medicine Launches FoundationOne™ Heme, …
https://www.mskcc.org/news-releases/foundation-medicine-launches-foundationone-heme-developed-collaboration-mskcc
WEBDec 7, 2013 · FoundationOne Heme uses comprehensive, clinical next-generation sequencing (NGS) to assess routine cancer specimens for all genes that are currently known to be somatically altered and unambiguous drivers of oncogenesis in hematologic malignancies, as well as many sarcomas and pediatric cancers.
DA: 99 PA: 9 MOZ Rank: 95